C1S (Sutimlimab Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA003657MB3HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
C1s VH4V2 research-grade biosimilar; BIVV009 research-grade biosimilar; BIVV-009 research-grade biosimilar; Enjaymo research-grade biosimilar; Sutimlimab research-grade biosimilar; Sutimlimab (genetical recombination) (JAN) research-grade biosimilar; Sutimlimab (USAN/INN) research-grade biosimilar; sutimlimab-jome research-grade biosimilar; TNT009 research-grade biosimilar; TNT-009 research-grade biosimilar ;C1S antibody; Complement C1s subcomponent antibody; EC 3.4.21.42 antibody; C1 esterase antibody; Complement component 1 subcomponent s [Cleaved into: Complement C1s subcomponent heavy chain antibody; Complement C1s subcomponent chain A antibody; Complement C1s subcomponent light chain antibody; Complement C1s subcomponent chain B] antibody
Species Reactivity
Human
Immunogen
Recombinant Human C1S protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to sutimlimab, targeting C1s (complement component 1s), a serine protease within the classical complement pathway. C1s functions as the enzymatic subcomponent of the C1 complex, cleaving C4 and C2 to initiate the complement cascade. This protease plays a critical role in immune-mediated hemolytic conditions, particularly cold agglutinin disease (CAD), where aberrant complement activation leads to red blood cell destruction. Dysregulated C1s activity has also been implicated in various autoimmune disorders and complement-mediated pathologies.

Sutimlimab represents a first-in-class C1s inhibitor that selectively blocks classical pathway activation while preserving lectin and alternative pathway functions. This biosimilar antibody provides researchers with a valuable tool for investigating complement-mediated mechanisms in hemolytic anemias, autoimmune diseases, and inflammatory conditions. It enables studies of C1s-specific inhibition in disease models and facilitates exploration of therapeutic strategies targeting the classical complement pathway. The antibody supports diverse immunological research applications examining complement regulation and immune system modulation.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.
Gene References into Functions
  1. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. PMID: 24695853
  2. Data indicate that complement C1s mRNA level was low in ICR-derived glomerulonephritis (ICGN) mice liver as compared with age-matched ICR mice. PMID: 23989031
  3. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4. PMID: 23592783
  4. Four positively charged amino acids on the serine protease domain appear to form a catalytic exosite that is required for efficient cleavage of C4 in the classical pathway of complement. PMID: 22855709
  5. Detailed mapping of post-translational modifications and insights into the C1r/C1s binding sites. PMID: 20008834
  6. Interaction with the prime side residues at the cleavage point in C1s enhances the affinity of the enzyme for complement 2 and complement 4 substrates; these prime subsite residues mediate positive cooperativity in the cleavage of the substrate. PMID: 14674770
  7. full specificity of the enzyme using a randomized phage display library PMID: 16169853
  8. There are splice variants of C1s mRNA transcripts in normal human cells PMID: 18062908

Show More

Hide All

Involvement in disease
Complement component C1s deficiency (C1SD); Ehlers-Danlos syndrome, periodontal type, 2 (EDSPD2)
Protein Families
Peptidase S1 family
Database Links

HGNC: 1247

OMIM: 120580

KEGG: hsa:716

STRING: 9606.ENSP00000328173

UniGene: Hs.458355

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*